Contineum Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 31
- Market Cap
- $511.1M
- Website
- http://www.contineum-tx.com
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Study of PIPE-791 for Subjects with Chronic Osteoarthritis Pain or Chronic Low Back Pain
- Conditions
- Chronic Osteoarthritis PainChronic Low Back Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Contineum Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT06810245
- Locations
- 🇺🇸
Arizona Research Center, Phoenix, Arizona, United States
🇺🇸Drug Studies America, Marietta, Georgia, United States
🇺🇸Drug Trials America, Hartsdale, New York, United States
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisMultiple SclerosisMultiple Sclerosis, MSMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, ProgressiveMultiple Sclerosis, Secondary ProgressiveHealthyHealthy Volunteers
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Contineum Therapeutics
- Target Recruit Count
- 28
- Registration Number
- NCT06683612
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Drug: PIPE-307 Dose ADrug: PIPE-307 Dose BDrug: Placebo
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Contineum Therapeutics
- Target Recruit Count
- 168
- Registration Number
- NCT06083753
- Locations
- 🇺🇸
Xenosciences, Phoenix, Arizona, United States
🇺🇸Arizona Neuroscience Research, LLC, Phoenix, Arizona, United States
🇺🇸Alta Bates Summit Medical Center, Berkeley, California, United States
Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Contineum Therapeutics
- Target Recruit Count
- 56
- Registration Number
- NCT05983939
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Contineum Therapeutics
- Target Recruit Count
- 6
- Registration Number
- NCT04941781
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
- Prev
- 1
- 2
- Next
News
Contineum Therapeutics On Track for Key Clinical Milestones with PIPE-791 and PIPE-307 Programs
Contineum Therapeutics expects topline data from its PIPE-791 Phase 1b PET trial in Q2 2025 and PIPE-307 Phase 2 VISTA trial for relapsing-remitting multiple sclerosis in H2 2025, affirming its clinical development timeline.
Contineum Therapeutics Completes Enrollment in Phase 2 Trial of PIPE-307 for Relapsing-Remitting Multiple Sclerosis
Contineum Therapeutics has completed enrollment of 168 patients in its Phase 2 VISTA trial evaluating PIPE-307 for relapsing-remitting multiple sclerosis (RRMS).
Contineum Therapeutics Initiates Dosing in Phase 1b Trial of PIPE-791 for Multiple Sclerosis
Contineum Therapeutics has commenced patient dosing in a Phase 1b clinical trial evaluating PIPE-791, an LPA1 receptor antagonist, for the treatment of relapsing-remitting multiple sclerosis (RRMS).
IPF Drug Development Heats Up with Novel Targets and Clinical Advances
• Refoxy Pharma secured $9.58 million to advance its FOXO3-targeting IPF drug, RP-01, aiming to modulate tissue repair mechanisms. • Boehringer Ingelheim plans to submit an NDA for nerandomilast after a successful Phase 3 trial showing improved lung function in IPF patients. • Endeavor BioMedicines' ENV-101 and Insilico Medicine's ISM001-055 demonstrate promising results in improving lung function and reducing fibrosis in Phase 2 trials. • Bristol Myers Squibb's BMS-986278, an LPA1 antagonist, received FDA Breakthrough Therapy Designation after reducing the rate of FVC decline by 69% in a Phase 2 study.